Patent · US Active

Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis

US10058527B2 · kind B2 · utility

1Cited by
0References
6Claims
0Family size

Assignees

Inventors

Key dates

Filing dateAug 18, 2014
Grant dateAug 28, 2018
Priority date
Expiry dateAug 18, 2034

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K31/22
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.